Oncoinvent ASA
Clinical-stage biotech developing radiopharmaceutical therapies for peritoneal cancers.
OCIN | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NO0010779341 (+1 more)
- LEI:
- 54930076H5GUZRMSNR39
- Country:
- Norway
- Address:
- Gullhaugveien 7, 0484 Oslo
- Website:
- https://www.oncoinvent.com/
- Sector:
- Manufacturing
Description
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-03 08:55 |
Mandatory notification of trade
|
English | 2.4 KB | ||
| 2025-10-31 08:30 |
Oncoinvent appoints Dr. Ramzi Amri as new CFO - Attachment: 251031_Oncoinvent_C…
|
English | 167.8 KB | ||
| 2025-10-31 08:30 |
Oncoinvent appoints Dr. Ramzi Amri as new CFO
|
English | 4.9 KB | ||
| 2025-10-29 22:17 |
Financial calendar
|
English | 683 bytes | ||
| 2025-10-29 17:38 |
Merger of BerGenBio and Oncoinvent completed - Attachment: 2025_10_29_merger_co…
|
English | 39.2 KB | ||
| 2025-10-29 17:38 |
Merger of BerGenBio and Oncoinvent completed
|
English | 4.5 KB | ||
| 2025-10-29 15:16 |
Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial…
|
English | 181.9 KB | ||
| 2025-10-29 15:16 |
Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial…
|
English | 5.8 KB | ||
| 2025-10-29 07:00 |
BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent - At…
|
English | 34.7 KB | ||
| 2025-10-29 07:00 |
BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent
|
English | 3.2 KB | ||
| 2025-10-24 07:59 |
BerGenBio and Oncoinvent - Key Dates for Completion of Merger - Attachment: 202…
|
English | 46.5 KB | ||
| 2025-10-24 07:59 |
BerGenBio and Oncoinvent - Key Dates for Completion of Merger
|
English | 9.5 KB | ||
| 2025-10-20 10:00 |
Financial calendar
|
English | 683 bytes | ||
| 2025-10-20 10:00 |
Finansiell kalender
|
Norwegian | 664 bytes | ||
| 2025-10-08 07:00 |
Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Tre…
|
English | 180.4 KB |
Automate Your Workflow. Get a real-time feed of all Oncoinvent ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oncoinvent ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oncoinvent ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
